

A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab. GINECO-OV236b/ENGOT-ov29

J.E. Kurtz, E. Pujade-Lauraine, A. Oaknin, L. Belin, I. Tsibulak, D. Cibula, I. Vergote, O. Rosengarten, M. Rodrigues, N. de Gregorio, J. Martinez-Garcia, P. Pautier, M.A. Mouret Reynier, F. Selle, V. D'Hondt, F. Joly Lobbedez, E. Bultot Boissier, A. Floquet, P.-E. Heudel, F. Heitz











ENG

GINECO



Declaration of interests

Jean-Emmanuel KURTZ

Advisory boards: AstraZeneca, Chugai, Eisai, Merck-Serono, Tesaro Speaker/honoraria: Bristol Myers Squibb, Clovis Oncology, Mersana, Seagen Travel expenditure: AstraZeneca, Glaxo SmithKline, PharmaMar, Roche Research funding: none





Rationale

In patients with ovarian cancer relapsing with a platinum-free interval > 6 months:

- Carboplatin (Cb) combination with either pegylated liposomal doxorubicin (PLD)¹, gemcitabine² or paclitaxel³ is a standard of care
- When added to chemotherapy, bevacizumab increases response rate and prolongs PFS⁴⁻⁶
- An objective response of 13.6% has been reported in patients with prior CR or PR to platinum-based chemotherapy when treated with single agent check-point inhibitor (CPI) blocking the PD-1/PD-L1 axis⁷
- Addition of CPI has been reported to increase chemotherapy and/or bevacizumab activity in other tumors ⁸⁻⁹



1- Pujade-Lauraine E, et al. JCO 2010; 2-Pfisterer J, et al. JCO 2006; 3-Parmar MK, et al. Lancet 2003; 4-Aghajanian C, et al. JCO 2012; 5-Coleman R, et al, Lancet Oncol 2017; 6-Pujade-Lauraine E, et al. JCO 2014; 7-Disis ML, et al. JAMA Oncol 2019; 8- Rini BI, et al. Lancet 2019; 9- Socinski MA N Engl J Med 2018




ATALANTE trial design

- Relapsed non-mucinous
 epithelial OC
- Platinum-free interval >6 mos
- 1 or 2 prior chemotherapy lines
- ECOG PS ≤1

Stratification factors

- PD-L1 ≥ 1% on immune cells vs <1% vs unknown (Ventana clone SP142)
- Chemotherapy: Cb-PLD or gemcitabine or paclitaxel
- Platinum-free interval: 6-12 vs >12 months






- **Co-primary endpoints** are progression-free survival (PFS1) according to investigator in the ITT and PD-L1-positive populations
- Secondary endpoints: TSST, TFST, OS, safety (NCI CTCAE V 4.03) and HrQoL (EORTC QLQ-C30, QOLQ OV-28, EQ5D-5L)



Statistical considerations

- PFS1 was analyzed using a Cox model adjusted by stratification factors with a two-sided α level at 0.025 and 80% power for each PFS co-primary in the ITT and PD-L1-positive populations
- 491 events in the ITT and 186 in the PD-L1-positive populations were expected to show a reduction in the risk of progression of 27% (difference of median PFS1 of 4.8 months) and of 38% (difference of median PFS1 of 9.0 months), respectively
- Following a hierarchical approach, if either of the co-primary PFS1 comparisons was significant, overall survival could then be analyzed in both the ITT and PD-L1-positive populations



*MDD=Minimal Detectable Difference



Baseline <u>characteristics (1)</u>





	Atezo (N=410)	Placebo (N=204)
Median (IQR) patient age, years	63 [55-70]	64 [55-71]
Histology, n (%)		
Serous high grade	346 (84)	169 (83)
Serous low grade	32 (8)	
Endometrioid high grade	. ,	8 (4) 11 (5)
Clear cell	12 (3) 8 (2)	
Others		9 (4)
ECOG, n (%)	12 (3)	7 (3)
0	077 (00)	404 (04)
1	277 (68)	131 (64)
2	131 (32)	72 (35)
Number of prior lines, n (%)	2 (<1)	0 (0)
1		
2	307 (75)	147 (72)
Last line of therapy, n (%)	103 (25)	57 (28)
Platinum		
Bevacizumab	410 (100)	204 (100)
PARPi	203 (50)	107 (52)
FARFI	74 (18)	40 (20)
Debulking surgery (within 6 months of inclusion), n (%)		
Complete macroscopic resection	62 (15)	30 (15)
	34 (8)	20 (10)



Baseline characteristics (2)



	Atezo (N=410)	Placebo (N=204)
PD-L1 status, n (%)		
<u>></u> 1%	156 (38)	77 (38)
<1%	196 (48)	102 (50)
Inconclusive/missing	58 (14)	25 (12)
BRCA status, n (%)		
Mutant	40 (10)	32 (16)
Non-mutant	241 (59)	118 (58)
Inconclusive/missing	129 (31)	54 (26)
Chemotherapy chosen by the investigator, n (%)		
Carboplatin-PLD	259 (63)	128 (63)
Carboplatin-gemcitabine	118 (29)	58 (28)
Carboplatin-paclitaxel	33 (8)	18 (9)





Treatment exposure

	Atezo (N=410)	Placebo (N=204)
Median (IQR) duration of treatment, months	11.1 (6.7–16.8)	11.1 (8.3-15.1)
Study drug end of treatment, reason, n (%)		
Disease progression	255 (62)	148 (73)
Adverse event	100 (24)	34 (17)
As per protocol	9 (2)	0 (0)
Consent withdrawn	9 (2)	2 (1)
Others	37 (9)	20 (10)




Jean-Emmanuel KURTZ

congress

PARIS 2022

Progression-free survival (ITT)



Treatment Arm	N	Event N (%)	PFS at 6m % (95% Cl)	PFS at 12m % (95% CI)	PFS at 18m % (95% Cl)	Median PFS (95% CI)
Atezo	410	348 (85)	88 (85-91)	56 (51- 61)	32 (28-37)	13.5 mos (12.2-14.2)
Placebo	204	187 (92)	91 (87- 95)	46 (39- 53)	23 (18-30)	11.3 mos (11.0-13.5)
Hazard ratio= 0.83 [0.69-0.99]					P=.041	

median follow-up : 36.6 months


The ATALANTE trial did not meet its first co-primary objective: PFS1 in the ITT population







Progression-free survival (PD-L1 positive)



Treatment Arm	N	Events N (%)	PFS at 6m % (95% CI)	PFS at 12m % (95% Cl)	PFS at 18m % (95% Cl)	Median PFS (95% CI)
Atezo	156	124 (79)	93 (89-97)	64 (57- 72)	39 (32-47)	15.2 mos (13.6-17.3)
Placebo	77	66 (86)	92 (86- 98)	55 (45- 68)	31 (22-44)	13.1 mos (11.3-16.5)
	Hazard ratio= 0.86 [0.63-1.16]					


The ATALANTE trial did not meet its coprimary objective: PFS1 in the PD-L1 positive population

Jean-Emmanuel KURTZ

PFS analysis by subgroup (ITT)

(•	GINECO	ENGOT European Network of Gynaecological Oncological Trial groups	GCIG GYNECOLOGIC CANCER INTERGROUP
		dynaecological oncological mai groups	CANCER INTERGROUP


A	Atz (n)	Placebo (n)	HR (95% CI)
Age (years)	005		0.70 (0.04 0.07)
< 70	305	141	0.79 (0.64 - 0.97)
≥ 70	105	63	0.88 (0.64 - 1.22)
Adenocarcinoma type	050	100	0.00 (0.00 0.00)
Serous high grade or Endometrioid Grade 2/3	358	180	0.82 (0.68 - 0.99)
Other	52	24	0.70 (0.41 - 1.19)
Number of previous lines	307	147	0.04 (0.65 4)
1 2	103	57	0.81 (0.65 - 1)
2 Platinum-free interval	105	57	0.82 (0.58 - 1.15)
	100	45	1 (0 70 1 12)
6-12 months	103	45	1 (0.70 - 1.43)
> 12 months	307	159	0.75 (0.61 - 0.92)
Prior Bevacizumab	240	120	0.02/0.74 4.45
Yes	248 162	130 74	0.92 (0.74 - 1.15)
No	102	74	0.67 (0.50 - 0.91)
Tumor size	96	26	0.01/0.50 1.44)
No measurable target		36	0.91 (0.59 - 1.41)
Sum of target lesions diameter ≥ 5cm	150	63	0.98 (0.72 - 1.33)
Sum of target lesions diameter < 5cm	164	105	0.68 (0.53 - 0.88)
PDL1 expression	400	100	0.00 (0.07 4.40)
Negative	196	102	0.86 (0.67 - 1.10)
Positive	156	77	0.80 (0.59 - 1.07)
Not informative	58	25	0.69 (0.42 - 1.13)
CD8-PDL1	005	101	0.00 (0.04 0.00)
Negative	265	131	0.80 (0.64 - 0.99)
Both positive	95	50	0.92 (0.63 - 1.35)
BRCA mutation	10	22	0.67 (0.41 1.00)
Germline or somatic mutation	40	32	0.67 (0.41 - 1.09)
No mutation	241	118	0.74 (0.59 - 0.94)
Inconclusive	129	54	1.04 (0.74 - 1.47)
CA-125 level at baseline	007	110	0.00 (0.70 4.40)
Abnormal ≥ 100 kU/L	227	113	0.89 (0.70 - 1.12)
Abnormal <100 kU/L	88	48	0.62 (0.43 - 0.91)
Normal	92	43	0.80 (0.53 - 1.21)
Chemotherapy cohort	454	70	0.70 (0.50 4.04)
Paclitaxel or Gemcitabine	151	76	0.78 (0.58 - 1.04)
PLD	259	128	0.82 (0.66 - 1.03)



No significant interaction with atezolizumab treatment was found in any subgroup, including patients with CD8+/PD-L1+ tumors on biopsy at study entry



Time to second subsequent treatment (TSST)




Treatment Arm	N	TSST at 12m % (95% CI)	TSST at 24m % (95% Cl)	TSST at 36m % (95% Cl)	Median TSST (95% CI)
Atezo	410	85 (81-89)	49 (44-54)	31 (26-37)	23.9 mos (22.6-26.5)
Placebo	204	83 (78-88)	43 (36-50)	19 (14-27)	21.4 mos (19.0-24.0)
		Hazard r			

- TSST was a surrogate of PFS2
- The TSST prolongation in adding Atezo to chemotherapy+Bev remains small



GINECO EUROPAN NEtwork of Gynaecological Oncological Trial groups

Overall survival (ITT)



Treatment Arm	N	Events N (%)	Median 0S (95% Cl)	
Atezo	410	207 (51)	35.5 mos (32.4-41.3)	
Placebo	204	126 (62)	30.6 mos (27.9-33.6)	
	Hazard ratio= 0.81 [0.65-1.01]			

- Overall survival data are not yet mature (333 events out of 491 expected): longer follow-up is required
- Trend in favor of the atezolizumab arm in the ITT population

Jean-Emmanuel KURTZ



Overall safety

AEs, n [§] (%)	Atezo (N=410)	Placebo (N=204)
All grade	409 (100)	202 (99)
Grade 3/4	360 (88)	175 (86)
treatment-related	317 (77)	143 (70)
AEs with fatal outcome	14 (3)	5 (2)
treatment-related	3 (1)	2 (1)
SAEs	293 (71)	120 (59)
treatment-related	144 (35)	50 (25)
AEs leading to any treatment discontinuation	184 (45)	84 (41)
to atezo/placebo discontinuation	101 (25)	37 (18)
to bevacizumab discontinuation	137 (33)	57 (28)
AEs leading to atezo/placebo interruption	265 (65)	128 (63)

[§]Number of patient with at least one event

3 patients in the atezolizumab arm had fatal AEs related to treatment (cardiac arrest, peritonitis and acute myelogenous leukemia). 2 patients in the placebo arm had fatal AEs related to treatment (pulmonary embolism and bowel perforation)



Immune-related infusion reactions & auto-immune disorders (AESI)


AESI, n [§] (%)	Atezo (N=410)	Placebo (N=204)
All grade AESI for atezolizumab	109 (27)	30 (15)
Grade 3/4 AESI treatment-related	52 (13) 25 (6)	16 (8) 5 (2)
Immune related infusion reaction (all grades)	34 (8)	9 (4)
Autoimmune disorders (all grades)	91 (22)	23 (11)
Hypothyroidism	45 (11)́	10 (5)
Hyperthyroidism	8 (2)	5 (2)
Hepatitis or transaminitis	9 (2)	1 (<1)
Colitis or severe diarrhea	4 (1)	4 (2)
Pancreatitis	4 (1)	0 (0)
Pneumonitis	3 (1)	0 (0)
Diabetes mellitus	2 (<1)	0 (0)
Adrenal insufficiency	2 (<1)	0 (0)
Ocular	1 (<1)	0 (0)
Nephritis	1 (<1)	0 (0)
Other	27 (7)	5 (2)



[§]Number of patients with at least one event



Health-related quality of life (HRQL)



No significant mean change from baseline EORTC QLQ-30 global score in either arm

Jean-Emmanuel KURTZ

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.



Conclusions

- The ATALANTE trial evaluated the addition of atezolizumab to standard platinum-based chemotherapy in combination with bevacizumab in patients with late relapsing OC (PFI> 6 months)
- The ATALANTE trial did not meet its PFS primary objective in either ITT or PD-L1-positive populations
- Encouraging OS data warrant further analyses with more follow-up
- Safety data were consistent with the individual profile of each drug and their combination
- Further research on ATALANTE biopsy samples is required to understand better the immunological landscape of late relapsing OC



Acknowledgements

L CHAIGNEAU

We thank all the patients, their families, the investigators, and the staff.

P FOLLANA

. GINECO **GINECO - France** JE KURTZ S ABADIE-LACOURTOISIE C ABDEDDAIM J ALEXANDRE P AUGEREAU D AVENIN M AZEMAR N BABA-HAMED **O BALLY J BARRIERE** F BAZAN D BERTON N BONICHON-LAMICHHANE N BONNIN E BOUGHALEM **R BOUSTANY GRENIER** PE BRACHET F BROCARD E BULTOT-BOISSIER MA CAPPIELLO-BATALLER **H CASTANIE**

JS FRENEL C CHAKIBA D CHOCTEAU-BOUJU **G FREYER** P COMBE D GARBAY-A COMTE DECOOPMAN E COQUAN C GAVOILLE V GIRRE C COSTAN L GLADIEFF PH COTTU L CROUZET F GOLDWASSER H CURE A GRATET J DAUBA J GRENIER H DAWOOD AC HARDY-BESSARD L DE COCK PE HEUDEL T DE LA MOTTE ROUGE F JOLY C DEBELLEIX A JOUINOT C DELBALDO E KALBACHER M DEMARCHI MC KAMINSKY M DESLANDRES L LANCRY-LECOMTE R DESPAX **R LARGILLIER** FIFDU V D'HONDT AF DILLIES-LEGRAIN A LEARY A DONNADIEU C LEBRETON C DUBOT C LEFEUVRE-PLESSE JM EXTRA A LESOIN M FABBRO T L'HARIDON C FALANDRY J LONG F FITENI A LORTHOLARY A FLOQUET JP LOTZ

Sponsor ARCAGY-GINECO O. Baconnet, C. Montoto-Grillot, Y. Omri, E. Nzeymana, S. Armanet, B. Votan

congress

Study group coordinators AGO De: A. Krueger AGO Au: A. Riha BGOG: E. Peeraer CEEGOG: I. Nohova GEICO: A. Levin

M MARTINEZ J MEDIONI E MERIAUX **J MEUNIER** L MOÏSE JF MOULIN MA MOURET-REYNIER M MOUSSEAU P PAUTIER J PERON C PERRIN T PETIT D PETRAN F PRIOU M PROVANSAL N RABAN I RAY-COQUARD P REGNAULT DE LA MOTHE C RIEDL M RODRIGUES C ROEMER-BECUWE R SABATIER F SAVINELLI C SEBBAG F SELLE

IDMC

C. Sessa

D. Provencher

Euraxi Pharma

A. Pommier

J. Paul

L MANSI

J MARTIN-BABAU

M TIMAR-DAVID O TREDAN P TRESCA V TRILLET-LENOIR T VALENTIN YA VANO B YOU AGO Study Group AGO De - Germany

P SOULIE

D SPAETH

R SVERDLIN

F HEITZ H BRONGER P BUDERATH N DE GREGORIO T FEHM EM GRISCHKE M GROPP-MEIER A HARTKOPF C JACKISCH M KOEGEL A MUELLER TW PARK-SIMON

Statisticians

B. Asselain

M. Turinici

L. Belin

I RUNNEBAUM F SCHOCHTER B SCHMALFELDT

B SCHNAPPAUF J SEHOULI F TRILLSCH P WIMBERGER



GEICO - Spain A OAKNIN JD ALARCON S ALONSO A ALONSO HERRERO **P BARRETINA** A CASADO C CHURRUCA I FERNANDEZ L GABA J GARCIA-DONAS S GONZALEZ **G MARQUINA** J MARTINEZ GARCIA A REDONDO D VICENTE

Centre de Ressources **Biologiques of ARCAGY-GINECO (Institut Curie)** A. Degnieau E. Glais

AGO Au - Austria C MARTH S AUST E PETRU A REINTHALLER



ISGO - Israel **O ROSENGARTEN**



C SCHAUER

CEEGOG - Czech Republic D CIBULA



BGOG - Belaium I VERGOTE S ALTINTAS H DENYS E VAN NIEUWENHUYSEN

Funding

J. Kellv

Hoffmann-La Roche Ltd

Medical writing support

European Network of Gynaecological Oncological Trial group





Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.



18